Board Considered and approve the audited financials result as on 31st March 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Qualitek Labs reported audited FY25 results with standalone revenue from operations rising 57% to Rs 4,586.48 lakh (vs Rs 2,918.38 lakh in FY24), driven by a full year of consolidated operations and inorganic growth. Standalone net profit grew 23% to Rs 528.33 lakh from Rs 430.73 lakh, while EPS on a basic basis stood at Rs 5.94 vs Rs 7.46 (lower due to fresh equity issuance). On a consolidated basis (first year of reporting), revenue was Rs 7,022.69 lakh with a net profit of Rs 768.36 lakh and EPS of Rs 7.08. During the year the company raised Rs 5,171.65 lakh via preferential allotment at a premium of Rs 188.33 per share, acquired a 49.99% stake in Interstellar Testing Centre (ITCPL) and a 100% stake in Quality and Testing Infosolution (QTIPL), and approved a share-swap to make ITCPL a wholly-owned subsidiary in FY26. Statutory auditor J Madan & Associates issued an unmodified opinion on both standalone and consolidated results.
The strong top-line growth is positive but margins compressed as expenses grew faster than revenue, raising concerns on profitability scalability. The large equity raise and pending share-swap will lead to further dilution, though acquisitions are expected to drive future revenue. Unmodified audit opinion and healthy operating cash flow of Rs 801 lakh are supportive signals for the stock.